Related Experiment Video
Updated: Feb 13, 2026
Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
Published on: February 10, 2023
The emerging role of immunotherapy in advanced urothelial cancers
William Tabayoyong1, Jianjun Gao2
1The University of Texas MD Anderson Cancer Center, Department of Urology.
Purpose Of Review:
Recent Food and Drug Administration (FDA) approval of five new immune checkpoint inhibitors for the treatment of metastatic urothelial cancer represents the first major treatment breakthrough for this disease since the introduction of combination chemotherapy over 30 years ago. This review examines the recent clinical trials leading to FDA approval of these agents, the current challenges facing immunotherapy and areas that require further research.
Recent Findings:
The programmed death 1 receptor (PD-1) and its ligand programmed death ligand-1 (PD-L1) are important negative regulators of immune activity, preventing destruction of normal tissues and autoimmunity. Aggressive bladder cancer cells express aberrantly high levels of PD-L1, hijacking the normal immune-regulatory pathway to evade detection and destruction by the immune system. Blockade of the PD-1/PD-L1 axis with immune checkpoint inhibitors augments the immune system's ability to eradicate bladder cancer with impressive safety and tolerability profiles.
Summary:
Recent clinical trials demonstrate that patients with metastatic urothelial carcinoma are responsive to immune checkpoint inhibitor therapy. Optimal treatment regimens are still under development, but activity has been demonstrated in both the first and second-line setting for metastatic disease.
Insights
The FDA has approved five new immune checkpoint inhibitors for metastatic urothelial cancer, marking a significant advancement. These therapies harness the immune system to combat advanced bladder cancer effectively.
Area of Science:
- Oncology
- Immunology
- Urothelial Carcinoma Research
Background:
- Metastatic urothelial cancer treatment has seen limited progress for over 30 years.
- Immune checkpoint inhibitors represent a major therapeutic breakthrough.
- Programmed death 1 receptor (PD-1) and its ligand (PD-L1) are key regulators of immune responses.
Purpose of the Study:
- To review recent clinical trials leading to FDA approval of immune checkpoint inhibitors.
- To examine current challenges and future research directions in urothelial cancer immunotherapy.
Main Methods:
- Analysis of recent clinical trial data for immune checkpoint inhibitors.
- Review of Food and Drug Administration (FDA) approval processes for new agents.
Main Results:
- Five new immune checkpoint inhibitors have received FDA approval for metastatic urothelial cancer.
- These agents target the PD-1/PD-L1 pathway, enhancing anti-tumor immunity.
- Positive safety and tolerability profiles observed in clinical trials.
Conclusions:
- Immune checkpoint inhibitors offer a new, effective treatment modality for metastatic urothelial carcinoma.
- Further research is needed to optimize treatment regimens and address challenges in immunotherapy.
- Activity demonstrated in both first- and second-line settings for metastatic disease.
Related Concept Videos
01:27Tumor Immunotherapy
01:27Emerging Adulthood
01:30Introduction Cardiac Emergencies
02:22Overview of Advanced Functional Groups
Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
00:56Extraction: Advanced Methods
01:29Applications of GIS: Disaster Management and Emergency Response